Navigation Links
Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial
Date:10/4/2007

MELBOURNE, Australia, Oct. 4 /PRNewswire-FirstCall/ -- Phosphagenics Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) and Nestle Nutrition (Nestle) today announced that they will jointly commence a phase 2 human clinical trial in Australia to establish the efficacy of Phosphagenics' Phospha E(R) in the management of metabolic syndrome.

Ethics approval has been obtained to conduct the double-blind phase 2 clinical trial, which will commence shortly.

Metabolic syndrome is characterized by a group of risk factors that increase the risk of diabetes, coronary heart disease and other diseases associated with plaque build up in artery walls, such as stroke. The American Heart Association estimates that 47 million U.S. residents have metabolic syndrome.

Dr. Esra Ogru, Executive Vice President Research & Development at Phosphagenics, said: "It is very rewarding to see Phospha E progress down the clinical trial path after years of pre-clinical testing. We have reached a very exciting stage of the development of this product and are delighted to be aligned with the world's largest nutrition company as our partner."

Nestle will fund the phase 2 clinical trials and will be granted a worldwide exclusive license for the use of Phospha E in medical foods, while Phosphagenics will manufacture and supply Phospha E to Nestle. The final commercial arrangements are expected to be completed by the end of this year.

This new collaboration builds upon two pre-clinical dose response trials performed by Nestle and Phosphagenics in 2006. The results of these trials confirmed that, when given orally, Phospha E significantly reduced many of the key biomarkers associated with metabolic syndrome, inflammation and cardiovascular disease.

About Phosphagenics Limited

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery o
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
5. New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
6. AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial with Alkaline Phosphatase in Acute Renal Failure
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Calif., Dec. 4 Suneva Medical, a privately-held aesthetic ... Ranker as Vice President and Chief Financial Officer. ... Medical,s general and administrative functions including finance, accounting, IT, ... serve on the Company,s senior management team. ,, ...
(Date:12/4/2009)... TARRYTOWN, N.Y., Dec. 4 Bayer Diabetes Care today announced ... Win Creativity Contest." Nick Jonas, of the Jonas Brothers, selected ... across the country. The grand prize is an in-person meeting ... type 1 diabetes like Nick, are: Caleb, age 6, from ...
(Date:12/4/2009)... anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder ... the comorbidities reported to occur more often in ... epilepsy versus those without an epilepsy diagnosis, according ... the U.S. ,, Findings from " CNS-Related Comorbidities ...
Breaking Medicine Technology:Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Dr Susan Blumenthal Meridian International Centers Global Health Chair Named Health Leader of the Year 49759 1Dr Susan Blumenthal Meridian International Centers Global Health Chair Named Health Leader of the Year 49759 2Dr Susan Blumenthal Meridian International Centers Global Health Chair Named Health Leader of the Year 49759 3New research discovers link between smoking and brain damage 49757 1New research discovers link between smoking and brain damage 49757 2NIH expands Human Microbiome Project 3B funds sequencing centers and disease projects 8963 1NIH expands Human Microbiome Project 3B funds sequencing centers and disease projects 8963 2NIH expands Human Microbiome Project 3B funds sequencing centers and disease projects 8963 3NIH expands Human Microbiome Project 3B funds sequencing centers and disease projects 8963 4NIH expands Human Microbiome Project 3B funds sequencing centers and disease projects 8963 5
... BOSTON--(BUSINESS WIRE)--Jun 25, 2007 - HepaLife Technologies, ... announced that new,data presented at an international ... cell line outperforms,current cell technologies at replicating ... important step towards the production of,a cell-culture ...
... WIRE)--Jun 25, 2007 - Pfizer announced today,that Lipitor ... stroke, coronary heart disease events and major coronary ... known coronary heart disease,but who had experienced a ... are from a new analysis of the landmark,Stroke ...
Other Medicine Technology:HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 2HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 3HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 4HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 5HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 6Lipitor Reduced the Risk of Coronary Events by Half and Stroke by,Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who,Experienced a Recent Stroke 2Lipitor Reduced the Risk of Coronary Events by Half and Stroke by,Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who,Experienced a Recent Stroke 3
(Date:12/6/2009)... that the loss of a key segment of DNA can ... to show that this kind of genetic alteration can cause ... , The study, led by Dr Sadaf Farooqi from the ... Trust Sanger Institute, looked at 300 children with severe obesity. ... types of mutation known as copy number variants (CNVs). CNVs ...
(Date:12/6/2009)... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ... pivotal Phase 2b 003-A1 study, known as the ... heavily pre-treated relapsed and refractory multiple myeloma patients. ... Joint Symposium at the 51st annual meeting of ... Orleans. Enrollment in this trial is complete (n=269), ...
(Date:12/6/2009)... Sleep Disorders information and Treatment site www.sleeping-with-a-sleeping-disorder.com ... problems with herbal or natural sleep aids from ... remedies for a good cause. The submissions will ... Sleep Aids ,Encyclopedia, by YOU, to be sold ... site will donate 100% of the proceeds ,from ...
(Date:12/5/2009)... significant scientific advances in the field of blood cancers, ... of how certain diseases progress in order to discover ... care. Research presented today at the 51st Annual Meeting ... therapies for managing multiple myeloma, the importance of advance ...
(Date:12/5/2009)... and myeloproliferative disorders are serious and often deadly ... Annual Meeting of the American Society of Hematology ... methods for patients suffering from acute promyelocytic leukemia, ... myelofibrosis that are based on a better understanding ...
Breaking Medicine News(10 mins):Health News:Genetic studies reveal new causes of severe obesity in childhood 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9
... been known that countries with rapidly developing economies may ... overnutrition. People living in poverty experience diseases that result ... suffer from diseases that result from an abundance of ... Health (HSPH) and the University of Bristol have examined ...
... beating heart could be new screening tool , TUESDAY, Sept. ... the hearts of pre-diabetic people before either diabetes or heart ... at the University of Texas Southwestern Medical Center discovered the ... a new screening tool for people at risk for diabetes ...
... Md., Sept. 4 Martek,s life,sDHA(TM),from microalgae ... triglycerides in male,hypertriglyceridemic patients, according to a ... American Journal of Clinical Nutrition. In this ... EPA,(eicosapentaenoic acid), the other omega 3 commonly ...
... destroys,enamel, CHICAGO, Sept. 4 Fruit, yogurt, citric ... but improper,consumption and overuse may lead to devastating and ... an online member poll conducted by,the Academy of General ... common today compared to five years ago., To ...
... withhold drugs because of side effect concerns, study finds , ... safety of asthma drugs may prevent asthmatic children from getting ... to data released in the September issue of Pediatrics ... more concerned about the side effects of asthma medications than ...
... Marlabs, Inc. has been named by,the Brown-Wilson Group ... Top 10 BPO,healthcare revenue cycle management companies. ... outsourcing users and,decision makers globally, garnering over 21,000 ... CEO Siby Vadakekkara attributes the recognition to their,commitment ...
Other Medicine News:Health News:Income inequality associated with overnourishment and undernourishment in India 2Health News:Fat Builds Up in Hearts Before Diabetes Onset 2Health News:Study Demonstrates Martek's Algal DHA Oil Improves Blood Triglyceride Lipid Levels 2Health News:Study Demonstrates Martek's Algal DHA Oil Improves Blood Triglyceride Lipid Levels 3Health News:Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion 2Health News:Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion 3Health News:Parents' Worries Hamper Kids' Asthma Treatment 2Health News:Marlabs in the Top 10 BPO Healthcare Revenue Cycle Management Companies 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: